Literature DB >> 19788660

Management of exudative retinal detachment in choroidal melanoma.

Syed K Gibran1, Kapil G Kapoor.   

Abstract

Exudative retinal detachment is the most common source of visual loss associated with malignant melanoma of the uveal tract. Management has historically been conservative, leading to irreversible visual loss from photoreceptor damage during the several months needed for post-radiation resolution. The purpose of this paper is to describe timely vitreoretinal surgical intervention for exudative retinal detachments associated with choroidal melanomas. This was an interventional case series including six consecutive patients with malignant melanoma who experienced VA reduction secondary to associated exudative retinal detachment. Patients underwent complete ophthalmic evaluation and B-scan ultrasound. Treatment included proton-beam radiation or brachytherapy, prognostic transretinal tumour biopsy with 25-gauge vitrector and surgical treatment of exudative retinal detachment, including vitrectomy and drainage of subretinal fluid at the time of irradiation. Successful management of exudative retinal detachments associated with choroidal melanomas was observed in all cases, with significant restoration of vision. Steady regression of tumour thickness was noted clinically and ultrasonographically, without extrascleral extension or metastasis, and with no recurrence of exudative retinal detachment found over follow up. In the present study, the investigators have showed effective surgical treatment of exudative retinal detachment associated with malignant melanoma. These patients had significant restoration of vision, confirming that timely intervention of exudative retinal detachment associated with malignant melanoma can reverse visual loss in these patients. These findings are in contrast to previous reports of irreversible visual loss after exudative retinal detachments, and suggest that photoreceptor atrophy might play a role in visual loss associated with chronic exudative retinal detachments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788660     DOI: 10.1111/j.1442-9071.2009.02127.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  7 in total

Review 1.  Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Authors:  Patrick Oellers; Prithvi Mruthyunjaya
Journal:  Melanoma Manag       Date:  2016-02-17

2.  Endodrainage, Tumor Photocoagulation, and Silicone Oil Tamponade for Primary Exudative Retinal Detachment due to Choroidal Melanoma Persisting after Proton Beam Therapy.

Authors:  Ira Seibel; Dino Cordini; Gregor Willerding; Aline Isabel Riechardt; Antonia Maria Joussen
Journal:  Ocul Oncol Pathol       Date:  2014-07-22

3.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

4.  Hidden Choroidal Melanoma Presented with Bullous Non-rhegmatogenous Retinal Detachment in a Myopic Asian Lady: A Rare Manifestation.

Authors:  Norihan Ibrahim; Zakariah Sakinah; Zulkifli Abdul Ghani; Mohtar Ibrahim
Journal:  Cureus       Date:  2019-03-27

5.  An Automatic Framework to Create Patient-specific Eye Models From 3D Magnetic Resonance Images for Treatment Selection in Patients With Uveal Melanoma.

Authors:  Mohamed Kilany Hassan; Emmanuelle Fleury; Denis Shamonin; Lorna Grech Fonk; Marina Marinkovic; Myriam G Jaarsma-Coes; Gregorius P M Luyten; Andrew Webb; Jan-Willem Beenakker; Berend Stoel
Journal:  Adv Radiat Oncol       Date:  2021-04-03

6.  Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma.

Authors:  Marcela Lonngi; Samuel K Houston; Timothy G Murray; Robert A Sisk; Christina L Decatur; Milena Cavalcante; Arnold M Markoe
Journal:  Clin Ophthalmol       Date:  2013-02-27

7.  Influence of Ranibizumab versus laser photocoagulation on radiation retinopathy (RadiRet) - a prospective randomized controlled trial.

Authors:  Ira Seibel; Daniela Vollhardt; Aline I Riechardt; Matus Rehak; Sabine Schmied; Petra Schiller; Oliver Zeitz; Martin Hellmich; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-28       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.